Tiny Gem Archives - Page 24 of 48

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

ThursdayJul 06, 2023 9:00 am

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3 Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023 Genprex is combining its lead product candidate, REQORSA, with…

WednesdayJul 05, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Contract Renewal Indicates Company’s Success in Supporting International Transports

Freight Technologies (aka Fr8Tech) has developed a technology solution that uses machine learning and artificial intelligence (“AI”) to help shipping and freighting companies optimize product transports and avoid costly errors Fr8Tech recently announced that one of its top clients, multinational insulation manufacturing company K-FLEX de México SA de CV, renewed its contract for using Fr8Tech’s core tech solution, Fr8App K-FLEX cited Fr8App’s benefits to the company during the difficult COVID-19 pandemic period and beyond as K-FLEX expanded its operations and approaches $1 billion in annual revenues Fr8Tech is continuing to expand its technology frontiers with the establishment of a dedicated…

FridayJun 30, 2023 2:40 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection crucial in commercial markets To date, Lexaria has a robust intellectual property portfolio with 34 patents granted and many more pending worldwide Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced…

FridayJun 30, 2023 11:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Announces a Significant Development for Platform Users –Samsara Integration

FRGT just announced its new integration with Samsara, the pioneer of Connected Operations(TM) Cloud The move is seen as a “gamechanger,” with Fr8App customers now able to view and leverage insights from Samsara’s vehicle telematics solution Fr8App’s management is confident that by connecting with industry leaders like Samsara, the company will continue to pave the way for streamlined logistics processes and improved visibility for customers In addition, the move solidifies Fr8App’s position as the most connected and integrable platform for cross-border shipping in North America Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping…

WednesdayJun 28, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

Lexaria Bioscience recently received four new patents granted in Canada and the United States In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market The company has conducted five human clinical studies that have provided insights into the potential…

TuesdayJun 27, 2023 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Advances Lidar Solutions Enabling Automatic Emergency Braking, NHTSA Pushes for New Rules

Automatic Emergency Braking (“AEB”) uses sensors to monitor and detect obstacles and apply the brakes to either prevent the collision or reduce impact severity The Insurance Institute for Highway Safety (“IIHS”) conducted a study revealing that AEB with pedestrian detection was associated with a 29%-30% reduction in pedestrian injury crash risk The U.S. Department of Transportation’s National Highway Traffic Safety Administration (“NHTSA”) recently announced a Notice of Proposed Rulemaking requiring AEB on all new passenger cars and light trucks Cepton’s Vista(R)-X90 Plus is billed as the “world’s smallest” lidar with extensive integration capabilities allowing manufacturers to seamlessly embed the system…

MondayJun 26, 2023 11:15 am

D-Wave Quantum Inc. (NYSE: QBTS) Supports Governments’ Investment in Near-Term Quantum Applications

D-Wave’s technology is geared toward optimization problems commonly faced by the public sector Governments worldwide are engaging with quantum computing to solve public sector problems and build domestic supply chains and workforces D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services focused on delivering value via practical quantum applications, is helping fuel the adoption of near-term quantum computing solutions against a backdrop of increased government assessment, investment and legislation. As more governments start to consider quantum applications and the use of quantum technologies to solve public sector challenges, D-Wave offers solutions oriented towards addressing optimization problems…

FridayJun 23, 2023 11:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Enters New Stage With Dedicated AI Development Division

Texas-headquartered Freight Technologies (aka Fr8Tech) is a technology innovation company dedicated to sustaining over-the-road (“OTR”) commercial shipments within the USMCA (formerly NAFTA) North American trading area The company’s core Fr8App product is a cloud-based freight matching platform that uses artificial intelligence and machine learning to help shippers and carriers match up their loads, capacity, and destinations Fr8Tech is growing its artificial intelligence development, appointing Dr. Umberto León-Domínguez to oversee the creation of a dedicated AI department Fr8App was recently cited by Google Maps Platform’s blog as an innovative use of advanced markers from the platform to interactively help end users…

FridayJun 23, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode

Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy The Phase 1 dose escalation portion of the study showed that REQORSA(R) was generally well tolerated, and there were no dose-limiting toxicities; Genprex also reported encouraging evidence of efficacy in this portion In April, Genprex announced that its research collaborators presented in vivo mouse data showing that Genprex’s…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem